Such financial sacrifices underscore relentless demand despite high costs.
Doctronic's Summer Health deal extends AI care to families seeking urgent virtual care, but clear guardrails on when clinician escalation is required will matter as much as convenience.
When bridal boutiques start asking customers to sign weight-loss waivers and bra companies redesign products for changing body elasticity, it's clear that GLP-1 medications have moved far beyond a healthcare story. As adoption of GLP-1 medications reaches 12% to 15% of the US population, per KFF survey data, retailers across every category are discovering that changing consumer behavior requires more than just smaller portion sizes.
J&J serves as a case study on the power of brand resilience during a prolonged court battle.
AI health scam ads are fooling vulnerable patients, making consumer education with trusted healthcare creators a growing imperative for credible health brands.
Over 80% of baby and toddler grocery products fit the description, even as parents seek simpler foods and greater ingredient transparency.
Labcorp rolls out direct-to-consumer genetic testing that can uncover risks beyond routine care, but its value depends on guidance from consumers' regular physicians.
Peptide access may soon broaden in the US as the FDA's final decision could legitimize peptide compounding, giving telehealth brands with compounding facilities a head start.
Consumers embrace ChatGPT for health questions, but may remain reluctant to connect sensitive health data with AI tools.
AI is fueling pre-appointment research, forcing doctors to validate information and pharma to maintain accurate and discoverable online content.
Cyclospora cases tied to fresh produce are mounting amid low confidence in the FDA and food safety, raising the value of transparent updates.
Smartphone access and QR sharing could ease fragmented care if people embrace it, but widespread adoption is far from guaranteed.
Trump's tariff reversal targets generic drugs, leaving low-margin manufacturers with few options beyond raising prices or exiting the US market.
Marketers are following the trend, as fiber emerges as a front-of-package selling point for supplement and food brands.
On today’s podcast, we go beyond the headlines to explore what’s driving the latest wave of GLP-1 momentum, why this represents a lasting shift rather than just another healthcare trend, the biggest misconception retailers still have about how these drugs are changing consumer behavior, and which parts of the retail playbook need to be rewritten as consumers change how they eat, shop, and live. Tune in for a discussion featuring Vice President of Content and host Suzy Davidkhanian, along with Senior Analysts Rajiv Leventhal and Rachel Wolff.
OpenAI's latest ChatGPT health advice lawsuit could force stronger AI medical guardrails.
Novo's GLP-1 ad lawsuit against Lilly could redefine the standards for comparative drug advertising in a market projected to reach $200 billion.
Its no-subscription Cirqa band joins a crowded field where AI features, not screens, set products apart.
With no confirmed source for the cyclospora outbreak, clear communication may be key to winning diners back.
Pharma marketers should match the influence of clinical proof, cost details, and patient voices to the values of each audience.